Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

New answers, efficacy data in MS
August 2019
SHARING OPTIONS:

OTTAWA, Canada—Preclinical data of Orion Biotechnology Canada Ltd.’s OB-002 (5P12-RANTES) from a murine model of multiple sclerosis (MS) was recently published in Science Translation Medicine. In a new preclinical model of multiple sclerosis that features early-life viral infection in the brain, it was found that sites of cleared virus turn into lesion sites associated with MS-like pathology when autoimmune encephalomyelitis (EAE) is induced. EAE lesions contain inflammatory leukocyte because sites of cleared virus are long-term production sites for CCL5, a ligand of CCR5. Systemic administration of OB-002 was found to fully block the development of the lesions and the associated pathology.
 
“It is very exciting to have identified a possible pathway linking virus infection early in life to MS pathology, and intriguing that it should be dependent on the activation of a single chemokine receptor,” said Prof. Doron Merkler, who led the work.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.